Patrick M. Boland

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le, Tae Won Kim, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2019 · 975 citations · Full text

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Tanios Bekaii‐Saab, Fang‐Shu Ou, Daniel H. Ahn et al. · The Lancet Oncology · 2019 · 270 citations · Full text

Gastrointestinal Oncology, Medicine, Cancer Management +7

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

John H. Strickler, Andrea Cercek, Salvatore Siena et al. · The Lancet Oncology · 2023 · 217 citations

Oncology, Medicine, Pathology +7

BDNF and NT-4/5 exert neurotrophic influences on injured adult spinal motor neurons

B. Friedman, David Kleinfeld, VM Verge et al. · Journal of Neuroscience · 1995 · 205 citations · Full text

Rdln Chat, Spinal Cord Injury, Neurotrophic Influences +14

Escaping the professional silo: an escape room implemented in an interprofessional education curriculum

Cheri Friedrich, Hilary Teaford, Ally Taubenheim et al. · Journal of Interprofessional Care · 2018 · 132 citations

Education, Allied Health Professions, Escape Room +18